Raphael Catane

9.2k total citations · 2 hit papers
133 papers, 7.2k citations indexed

About

Raphael Catane is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Raphael Catane has authored 133 papers receiving a total of 7.2k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Oncology, 35 papers in Pulmonary and Respiratory Medicine and 26 papers in Molecular Biology. Recurrent topics in Raphael Catane's work include Cancer Treatment and Pharmacology (16 papers), Prostate Cancer Treatment and Research (12 papers) and BRCA gene mutations in cancer (11 papers). Raphael Catane is often cited by papers focused on Cancer Treatment and Pharmacology (16 papers), Prostate Cancer Treatment and Research (12 papers) and BRCA gene mutations in cancer (11 papers). Raphael Catane collaborates with scholars based in Israel, United States and Germany. Raphael Catane's co-authors include Bella Kaufman, Beatrice Uziely, Alberto Gabizón, Nathan I. Cherny, Francisco J. Plaza Martín, Y. Barenholz, Tamar Safra, Bela Kaufman, Anthony H. C. Huang and Rivka Cohen and has published in prestigious journals such as Proceedings of the National Academy of Sciences, JAMA and Journal of Clinical Oncology.

In The Last Decade

Raphael Catane

131 papers receiving 6.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer

2004 1.3k citations E O’Brien, Nely Wigler et al. Annals of Oncology profile →
Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes.

1994 1.2k citations Raphael Catane, Beatrice Uziely et al. profile →

Peers

Countries citing papers authored by Raphael Catane

Since Specialization

Citations

This map shows the geographic impact of Raphael Catane's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raphael Catane with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raphael Catane more than expected).

Fields of papers citing papers by Raphael Catane

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raphael Catane. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raphael Catane. The network helps show where Raphael Catane may publish in the future.

Co-authorship network of co-authors of Raphael Catane

This figure shows the co-authorship network connecting the top 25 collaborators of Raphael Catane. A scholar is included among the top collaborators of Raphael Catane based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raphael Catane. Raphael Catane is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers 2016 ·Breast Cancer Research and Treatment ·Shani Paluch–Shimon, Eitan Friedman, Raanan Berger, Moshe Z. Papa, Maya Dadiani, (unknown), Moshe Shabtai, Dov Zippel, Mordechai Gutman, Talia Golan, Ady Yosepovich, Raphael Catane, (unknown), Bella Kaufman	31
2	Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients 2010 ·Clinical Cancer Research ·Michal J. Besser, Ronnie Shapira‐Frommer, Avraham J. Treves, Dov Zippel, Orit Itzhaki, Liat Hershkovitz, Daphna Levy, Adva Kubi, Einat Hovav, (unknown), Bruria Shalmon, Izhar Hardan, Raphael Catane, Gal Markel, Sara Apter, Alon Ben‐Nun, Iryna Kuchuk, Avichai Shimoni, Arnon Nagler, Jacob Schachter	352
3	Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin 2009 ·Oncogene ·Ingo Wolf, Yael Laitman, Tamar Rubinek, Lilach Abramovitz, Ilya Novikov, Rachel Beeri, Makoto Kuro‐o, H. Phillip Koeffler, Raphael Catane, L. S. Freedman, Ephrat Levy‐Lahad, Beth Y. Karlan, Eitan Friedman, Bella Kaufman	40
4	Hormone Receptor Expression Is Associated With a Unique Pattern of Metastatic Spread and Increased Survival Among HER2-Overexpressing Breast Cancer Patients 2009 ·American Journal of Clinical Oncology ·Shani Paluch–Shimon, Noa Ben-Baruch, Ido Wolf, (unknown), Juri Kopolovic, Anna Kruglikova, (unknown), Ady Yosepovich, Raphael Catane, Bella Kaufman	10
5	European Society for Medical Oncology (ESMO) Program for the Integration of Oncology and Palliative Care: a 5-year review of the Designated Centers’ incentive program 2009 ·Annals of Oncology ·Nathan I. Cherny, Raphael Catane, D. Schrijvers, (unknown), Florian Strasser	71
6	High efficacy of pre-operative trastuzumab combined with paclitaxel following doxorubicin & cyclophosphamide in operable breast cancer 2008 ·Acta Oncologica ·Shani Paluch–Shimon, Ido Wolf, Hadassah Goldberg, Ella Evron, Moshe Z. Papa, Moshe Shabtai, Daphna Barsuk, Ady Yosepovich, (unknown), Raphael Catane, Bella Kaufman	11
7	2133 2006 ·International Journal of Radiation OncologyBiologyPhysics ·Zvi Symon, Tatiana Rabin, (unknown), (unknown), D. Alezra, Theodore S. Lawrence, Dan Aderka, Ido Wolf, Raphael Catane, M. Raphael Pfeffer	4
8	MR-guided focused ultrasound surgery (MRgFUS) for the palliation of pain in patients with bone metastases—preliminary clinical experience 2006 ·Annals of Oncology ·Raphael Catane, Alexander Beck, Yael Inbar, Tatiana Rabin, Nogah Shabshin, S Hengst, Raphael M. Pfeffer, Arik Hanannel, Osnat Dogadkin, Boaz Liberman, Doron Kopelman	196
9	Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer breakdown → 2004 ·Annals of Oncology ·E O’Brien, Nely Wigler, Moshe Inbar, R. Rosso, Eva‐Maria Grischke, Armando Santoro, Raphael Catane, D G Kieback, Piotr Tomczak, Stephen P. Ackland, F. Orlandi, L. Mellars, Leila Alland, Craig Tendler	1311
10	Neoadjuvant imatinib for unresectable gastrointestinal stromal tumor 2004 ·Anti-Cancer Drugs ·Daniela Katz, Amiel Segal, (unknown), Oded Jurim, Petachia Reissman, Raphael Catane, Nathan I. Cherny	34
11	CMF (Cyclophosphamide, Methotrexate, 5-Fluorouracil) Versus CNF (Cyclophosphamide, Mitoxantrone, 5-Fluorouracil) as Adjuvant Chemotherapy for Stage II Lymph-Node Positive Breast Cancer 2002 ·American Journal of Clinical Oncology ·Ilan G. Ron, Nely Wigler, Riva Borovik, Tamar Peretz, Shulamith Rizel, Adi Shani, Joseph Brenner, (unknown), Harold J. Brenner, Samario Chaitchik, Raphael Catane, Moshe Inbar	1
12	CMF (Cyclophosphamide, Methotrexate, 5-Fluorouracil) Versus CNF (Cyclophosphamide, Mitoxantrone, 5-Fluorouracil) as Adjuvant Chemotherapy for Stage II Lymph-Node Positive Breast Cancer 2001 ·American Journal of Clinical Oncology ·Ilan G. Ron, Nely Wigler, Riva Borovik, G Brufman, Shulamith Rizel, Adi Shani, Joseph Brenner, (unknown), (unknown), Moshe Inbar, Harold J. Brenner, Samario Chaitchik, Raphael Catane	7
13	Cancer Pain 1999 ·Journal of Pain and Symptom Management ·Rama Sapir, Raphael Catane, (unknown), Nathan I. Cherny	50
14	Estimation of Creatinine Clearance Without 24-Hour Urine Collection—A Useful Guide During Cisplatin Therapy 1993 ·Acta Oncologica ·Nissim Haim, Samuel D. Oman, Noya Galai, (unknown), (unknown), Raphael Catane	15
15	Recurrence‐associated mortality in patients with differentiated thyroid carcinoma 1993 ·Journal of Surgical Oncology ·Yodphat Krausz, Beatrice Uziely, (unknown), (unknown), Raphael Catane, Benjamin Gläser	12
16	The use of monoclonal anti-CEA antibody immunohistochemistry in detecting the origin of oral cavity metastasis 1990 ·International Journal of Oral and Maxillofacial Surgery ·D.W. Nitzan, N Livni, Yitzhak Marmary, (unknown), J. Sela, Raphael Catane	9
17	Estramustine phosphate (estracyt) in advanced malignant melanoma resistant to DTIC treatment 1978 ·Proceedings of the American Association for Cancer Research ·Mukund S. Didolkar, Raphael Catane, Renata Fonseca Vianna Lopez, E. Douglas Holyoke	3
18	Preliminary clinical study of prednimustine in lung cancer. 1977 ·Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) ·(unknown), Raphael Catane, Hiroshi Takita, (unknown), A Mittelman, Gillian Murphy	3
19	New steroidal alkylating agents in advanced stage D carcinoma of the prostate. 1977 ·Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) ·A Mittelman, Raphael Catane, G.P. Murphy	8
20	A phase II study of high dose cis diammine dichloro platinum II (DDP) in non testicular tumors 1977 ·Proceedings of the American Association for Cancer Research ·Raphael Catane, H. O. Douglass, A Mittelman	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact